Document is current
Any future updates will be listed below
-
Authors
Haderk, Franziska https://orcid.org/0000-0001-9658-2778
Chou, Yu-Ting
Cech, Lauren https://orcid.org/0000-0002-3621-4129
Fernández-Méndez, Celia https://orcid.org/0000-0001-8593-5507
Yu, Johnny
Olivas, Victor
Meraz, Ismail M. https://orcid.org/0000-0001-9109-5196
Barbosa Rabago, Dora
Kerr, D. Lucas https://orcid.org/0000-0002-0557-8341
Gomez, Carlos
Allegakoen, David V.
Guan, Juan
Shah, Khyati N.
Herrington, Kari A. https://orcid.org/0000-0003-4925-8072
Gbenedio, Oghenekevwe M.
Nanjo, Shigeki https://orcid.org/0000-0001-8356-9849
Majidi, Mourad
Tamaki, Whitney https://orcid.org/0000-0002-1124-628X
Pourmoghadam, Yashar K.
Rotow, Julia K.
McCoach, Caroline E.
Riess, Jonathan W. https://orcid.org/0000-0001-7370-7304
Gutkind, J. Silvio https://orcid.org/0000-0002-5150-4482
Tang, Tracy T.
Post, Leonard
Huang, Bo https://orcid.org/0000-0003-1704-4141
Santisteban, Pilar https://orcid.org/0000-0002-2758-796X
Goodarzi, Hani https://orcid.org/0000-0002-9648-8949
Bandyopadhyay, Sourav https://orcid.org/0000-0003-3120-923X
Kuo, Calvin J. https://orcid.org/0000-0002-7427-5985
Roose, Jeroen P. https://orcid.org/0000-0003-4746-2811
Wu, Wei https://orcid.org/0000-0002-6556-067X
Blakely, Collin M. https://orcid.org/0000-0001-8134-3651
Roth, Jack A. https://orcid.org/0000-0002-8955-1313
Bivona, Trever G. https://orcid.org/0000-0001-5734-4128
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 4 January 2022
Accepted: 18 March 2024
First Online: 3 May 2024
Competing interests
: T.G.B. is an advisor to Array/Pfizer, Revolution Medicines, Springworks, Jazz Pharmaceuticals, Relay Therapeutics, Rain Therapeutics, Engine Biosciences, and receives research funding from Novartis, Strategia, Kinnate, and Revolution Medicines. J.A.R. is a consultant in Genprex, Inc. C.M.B. is a consultant to Amgen, and Blueprint Medicines and receives research funding from AstraZeneca, Novartis, Takeda, Spectrum, Roche, and Mirati. J.P.R. is a co-founder and scientific advisor of Seal Biosciences, Inc. and advisor for the Mark Foundation for Cancer Research. C.J.K. is an advisor to Surrozen, Inc., Mozart Therapeutics and NextVivo. J.S.G. reports consulting fees from Domain Pharmaceuticals, Pangea Therapeutics, and io9 and is the founder of Kadima Pharmaceuticals, all unrelated to the current study. J.W.R. is an advisor to Blueprint, Beigene, Daiichi Sankyo, EMD Serano, Turning Point, and Janssen, and is a consultant to Blueprint, Novartis, and Boehringer Ingelheim. J.W.R. receives research funding from Merck, Novartis, Spectrum, Revolution Medicine, AstraZeneca, and GlaxoSmithKline. T.T.T. and L.P. are employees of Vivace Therapeutics and have an equity interest in Vivace Therapeutics. The remaining authors declare no competing interests.
